Modafinil

# Research Output: Modafinil

## Chemical Identity

**PubChem CID:** 4236 (api_verified via get_pubchem_compound)
**IUPAC name:** 2-benzhydrylsulfinylacetamide [Ref 1] (consistent with brief seed data)
**Systematic name:** 2-[(diphenylmethyl)sulfinyl]acetamide (also rendered as 2-benzhydrylsulfinylacetamide)
**Molecular formula:** C₁₅H₁₅NO₂S [Ref 1]
**Molecular weight:** 273.4 g/mol [Ref 1]
**InChIKey:** YFGHCGITMMYXAQ-UHFFFAOYSA-N [Ref 1]
**CAS number:** 68693-11-8 (web-retrieved; could not be confirmed via PubChem API response)
**SMILES:** Not returned in PubChem API response; available at PubChem CID 4236 entry directly

**Stereochemistry:** Modafinil is a racemic compound consisting of R- and S-enantiomers in a 1:1 ratio. The R-enantiomer (armodafinil; trade name Nuvigil) is the longer-acting, pharmacodynamically dominant enantiomer. The R-enantiomer is eliminated approximately 3× more slowly than the S-enantiomer [Ref 18]. The S-enantiomer has a half-life of approximately 4 hours, while the R-enantiomer has a half-life of approximately 15 hours [Ref 18].

**Physical properties:** Modafinil is a white to off-white crystalline powder, practically insoluble in water and cyclohexane, sparingly soluble in methanol and acetone [Ref 33]. Melting point approximately 164–166°C (web-retrieved; not confirmed via primary published source identified in this research).

**Brief discrepancies:**
- SMILES and PubChem CID fields are blank in the brief. Both are now confirmed: CID = 4236; InChIKey = YFGHCGITMMYXAQ-UHFFFAOYSA-N.
- The brief's IUPAC field is blank; confirmed as 2-benzhydrylsulfinylacetamide.

---

## Pharmacology

### Primary Mechanism of Action

Modafinil is classified as an atypical dopamine transporter (DAT) inhibitor. Its primary mechanism is inhibition of dopamine reuptake via blockade of DAT, which elevates extracellular dopamine in wake-promoting brain regions [Ref 3, Ref 5]. Unlike classical stimulants, modafinil is a low-affinity DAT inhibitor (Ki ≈ 3 µM for R-modafinil vs. ~300 nM for cocaine) [Ref 23], and does not cause robust dopamine efflux or locomotor hyperactivity at therapeutic doses [Ref 1].

**Key evidence:**
- DAT knockout mice are completely unresponsive to modafinil's wake-promoting effects, demonstrating DAT is necessary for its action [Ref 3] (Wisor et al. 2001 [Ref 3]).
- PET imaging in humans (Volkow et al. 2009 [Ref 5]) confirmed that modafinil (200–400 mg) blocks DAT in the striatum including the nucleus accumbens, increasing extracellular dopamine. DAT occupancy at therapeutic doses is ~65–70% [Ref 8].
- Dopaminergic D1 and D2 receptors are both required for modafinil's arousal effects (Qu et al. 2008 [Ref 16]).

### Secondary/Indirect Neurochemical Effects

Modafinil has minimal direct binding affinity at norepinephrine (NET), serotonin (SERT), or histamine transporters [Ref 28]. However, downstream catecholamine changes drive indirect effects on multiple systems:

- **Norepinephrine:** Indirect elevation of NE in prefrontal cortex and hypothalamus, secondary to dopaminergic effects and possible direct adrenergic mechanisms [Ref 4, Ref 28]. Modafinil at 400 mg increases plasma and urine norepinephrine by 33% and 42% orthostatic increase respectively (Taneja et al. 2005 [Ref 17]).
- **Serotonin:** Indirect upregulation of cerebral 5-HT levels [Ref 7].
- **Histamine:** Modafinil activates hypothalamic histaminergic tuberomammillary neurons [Ref 11]; histamine contributes to wake promotion.
- **Orexin/Hypocretin:** Modafinil administration activates orexin-containing neurons (Chemelli et al. 1999 [Ref 30]), but the presence of orexin is NOT required for modafinil's wake-promoting effects — orexin-null mice show even greater wakefulness response to modafinil than wild-type mice (Willie et al. 2005 [Ref 29]).
- **Glutamate/GABA:** Modafinil increases glutamate and decreases GABA in the hypothalamus and other regions [Ref 4, Ref 11].

**⚠ FLAG — Pharmacological class "Norepinephrine reuptake inhibitor":** The brief lists "Norepinephrine reuptake inhibitor" as a pharmacological class. The published literature does not support this as a primary direct action. StatPearls [Ref 28] and the 2024 Hersey/Tanda review [Ref 1] both explicitly note modafinil has "minimal direct effects on norepinephrine transporters." The NE elevation is indirect. The generation agent should consider revising the pharmacological class to focus on DAT inhibition as the primary mechanism, with indirect NE/5HT/histamine/orexin/glutamate effects noted as secondary.

### Binding Affinity Data

Published Ki values are limited:
- DAT (human): Ki ≈ 3 µM for R-modafinil (low affinity compared to cocaine ~300 nM) [Ref 23]
- NET: minimal direct binding — no confirmed Ki from primary literature retrieved
- SERT: minimal direct binding
- D1, D2 receptors: indirect functional effects documented; direct binding Ki not established in literature found

Human PET data (Volkow 2009 [Ref 5]; Karila 2016 [Ref 8]): 200–400 mg oral produces ~65.6–70% DAT occupancy in striatum, demonstrating clinically significant DAT engagement despite low in vitro affinity.

### Pharmacokinetics

*Primary source: Robertson & Hellriegel 2003 [Ref 2]; StatPearls [Ref 28]*

| Parameter | Value |
|-----------|-------|
| Administration | Oral |
| Tmax | 2–4 hours |
| Elimination half-life | ~12–15 hours overall; R-enantiomer ~15h; S-enantiomer ~4h [Ref 18] |
| Steady-state | Achieved in 2–4 days |
| PK dose-dependence | Dose-independent between 200–600 mg/day [Ref 2] |
| Protein binding | ~60% (primarily to plasma albumin) [Ref 2] |
| Volume of distribution | ~0.9 L/kg [Ref 2] |
| Metabolism | Primarily hepatic amide hydrolysis; lesser CYP-mediated oxidation |
| Unchanged drug excreted | <10% [Ref 2] |

**CYP enzyme interactions** [Ref 2, Ref 28]:
- **Inhibitor:** Reversible inhibition of CYP2C19 in vitro
- **Inducer:** CYP1A2, CYP2B6, CYP3A4 (concentration-dependent induction in hepatocytes)
- **Suppressor:** CYP2C9 suppressed in vitro

**Special populations [Ref 6, Ref 28]:**
- Hepatic impairment: max dose 100 mg/day (reduced to 50% in severe impairment)
- Renal insufficiency: elevated modafinil acid levels; caution required
- Elderly: reduced elimination; lower doses advised
- Pregnancy: contraindicated (see Safety section)

**⚠ FLAG — Tolerance half-life discrepancy:** The brief lists "Half-life: 5 days" under tolerance data. This is NOT the elimination half-life (confirmed at 12–15 hours [Ref 2]). The "5 days" likely refers to an editorial estimate of tolerance decay half-life, not the pharmacokinetic half-life. No published primary source was found that specifically quantifies modafinil's tolerance half-life at 5 days. This value requires editorial review and a source citation.

---

## History

### Discovery and Development

Modafinil originates from research conducted by L. Lafon Ltd (Laboratoire Louis Lafon), a pharmaceutical company based in Maisons-Alfort, France, near Paris (Billiard & Broughton 2018 [Ref 15]):

- **1974:** Adrafinil (CRL-40028), a benzhydryl sulfinyl compound, was identified at Lafon during screening for novel molecules. It caused dose-dependent increases in motor activity in mice without peripheral sympathomimetic effects.
- **1977–1978:** Neurophysiologist Professor Michel Jouvet (University of Lyon) prescribed adrafinil to narcoleptic patients; results were inconsistent.
- **Pharmacokinetic studies** of adrafinil revealed modafinil as its primary active metabolite, leading to synthesis of modafinil as a standalone compound.
- **1983:** Jouvet and colleague Bastuji prescribed modafinil to narcolepsy and idiopathic hypersomnia patients with significantly improved results — substantial reductions in excessive daytime sleepiness and sleep attacks in the majority of patients [Ref 15].
- Lafon initially declined commercial development; Jouvet's advocacy prompted clinical trials.
- **1991:** Modafinil was used by the French army during the Gulf War (January–February 1991) to sustain military operations — representing a major real-world proof-of-concept deployment [Ref 15].
- **1992:** Official registration in France as Modiodal [Ref 15].
- **1994:** French prescription availability under Modiodal (some sources specify 1994; Billiard & Broughton 2018 note 1992 registration).
- **1998:** FDA approved modafinil (as Provigil, Cephalon Inc.) in the United States for narcolepsy [Ref 6, Ref 28].
- **January 27, 1999:** DEA placed modafinil in Schedule IV of the Controlled Substances Act [Ref 25].
- **2003:** FDA extended approval to shift work sleep disorder and obstructive sleep apnea/hypopnea syndrome (adjunct to CPAP) [Ref 6].
- **2007:** Armodafinil (R-modafinil; Nuvigil, Cephalon) approved by FDA as a separate drug.

---

## Subjective Effects

Subjective effects documented in controlled human studies [Ref 4, Ref 7, Ref 9, Ref 14, Ref 36]:

### Wakefulness and Alertness
- Robust wakefulness promotion, particularly in sleep-deprived or hypersomnolent subjects [Ref 3, Ref 13]
- Significantly reduces subjective sleepiness (Epworth Sleepiness Scale), maintenance of wakefulness test performance, and Maintenance of Wakefulness Test scores in narcolepsy [Ref 35]
- In 64-hour sleep deprivation: modafinil 300 mg and d-amphetamine 20 mg both improved mood, fatigue, sleepiness, reaction time, logical reasoning, and short-term memory vs. placebo; modafinil elicited fewer side effects [Ref 43]

### Cognitive Enhancement
- **Executive function:** Most consistently enhanced at both 200 mg and 400 mg in healthy non-sleep-deprived subjects — superior performance on tasks requiring planning, decision-making, and cognitive flexibility [Ref 7]
- **Attention:** Domain-specific enhancement of sustained attention at doses that do not induce hyperarousal or locomotor stimulation [Ref 9]
- **Working memory:** Enhanced at therapeutic doses; fMRI shows increased efficiency of prefrontal cortex activation during WM tasks (reduced BOLD signal for equivalent performance) [Ref 36]
- **Learning/memory:** Approximately half of studies show improvement [Ref 7]
- **Divergent creative thinking:** Some reports of impairment [Ref 7]

### Mood and Emotional Effects
- Trends toward reduced anxiety, decreased fatigue-inertia, and increased vigor-activity [Ref 36]
- Decreased amygdala reactivity to fearful stimuli — potential anxiolytic property at low doses [Ref 36]
- Modafinil does not produce robust euphoria or mood elevation comparable to amphetamines [Ref 1]
- Emotional enhancement documented in taxonomy — consistent with reduced negative affect

### Duration Data (from controlled studies)
- Onset: 20–60 minutes [Ref 2] (Tmax 2–4 hours for peak plasma concentration)
- Peak effects: Consistent with 3.5–5 hours (aligns with Tmax and pharmacokinetics)
- Total duration: 5–10 hours for primary effects, consistent with 12–15h half-life

### Effect Profile Note
Published literature supports the following effects from the brief's taxonomy:
- **Body:** Appetite suppression (headache, decreased appetite ≤10%), stimulation (wakefulness promotion), dizziness, nausea (5–10%), abnormal heartbeat (rare, at higher doses), dehydration sensation (not specifically documented but plausible with catecholamine activation), wakefulness, pupil dilation (sympathomimetic), headache (most common adverse event)
- **Feeling:** Anxiety (5–10% incidence [Ref 28]); emotional enhancement documented
- **Thinking:** Motivation enhancement, focus enhancement, and memory enhancement all documented in controlled trials [Ref 7, Ref 9]; thought acceleration less specifically documented than with amphetamine
- **Perception:** Olfactory hallucination and music enhancement — not documented in primary literature found; these effects may be idiosyncratic or user-reported only (⚠ FLAG: label as user-report-based if included); light sensitivity — not specifically documented in controlled studies

---

## Safety & Toxicity

### LD50 and Acute Toxicity

No lethal dose in humans has been established in published literature [Ref 6, Ref 28]. The brief's claim that "the LD50 for human beings has never been reached" is consistent with the published evidence — no published LD50 determination in humans exists. The toxicity profile at clinical doses (100–400 mg/day) is favorable.

Animal LD50 data (not found via primary API search; would require DrugBank/MSDS data). Supratherapeutic rat doses (600 mg/kg over 14 days) caused T-wave negativity in 37.5% of animals and isolated AV blockade (Canyurt et al. 2022 [Ref 24]) — animal data only.

**⚠ FLAG — "Acute: high; Chronic: high" toxicity designation:** The brief's toxicity ratings appear to encode "LD50 is high" (meaning hard to reach, therefore low toxicity), not "toxicity is high." This framing is ambiguous and potentially confusing. The published literature consistently describes modafinil as well-tolerated with low acute and chronic toxicity at therapeutic doses. The generation agent should clarify this framing.

### Overdose Presentation

From StatPearls [Ref 28] and published clinical reports:
- Hypertension, tachycardia, agitation, and/or psychosis are the most common manifestations
- Most frequent effects in overdose: tachycardia, insomnia, agitation, dizziness, anxiety
- Approximately 20% of overdose presentations require medical intervention
- Supportive care is typically sufficient; no specific antidote

### Serious Adverse Effects

**Dermatological (most serious class-level warning):**
- Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) reported in adults and children, primarily in post-marketing surveillance [Ref 33]
- Onset typically within 1–5 weeks of initiation; isolated cases after months of treatment
- Modafinil was denied FDA approval for pediatric ADHD in part due to SJS risk [Ref 37]
- Incidence in children and adolescents: higher rate of serious dermatological reactions than adults [Ref 6]

**Hypersensitivity:**
- Angioedema: reported post-marketing; advise immediate discontinuation at any sign [Ref 33]
- Multi-organ hypersensitivity: median onset 13 days (range 4–33 days) from initiation; at least one fatality reported in post-marketing experience [Ref 33]

**Cardiovascular:**
- 400 mg modafinil increases resting HR by ~9.2 bpm, systolic BP by 7.3 mmHg, diastolic BP by 5.3 mmHg (Taneja et al. 2005 [Ref 17])
- 42% increase in orthostatic norepinephrine; 81% increase in urinary epinephrine [Ref 17]
- Premature ventricular contractions (PVCs), ventricular arrhythmia, myocardial ischemia — rare but reported post-marketing [Ref 28]
- Caution strongly advised in patients with pre-existing cardiovascular disease, left-ventricular hypertrophy, uncontrolled hypertension, or unstable angina [Ref 28, Ref 33]

**Psychiatric:**
- Psychosis, hallucinations, mania, and suicidal ideation reported at therapeutic doses in post-marketing surveillance [Ref 28]
- Pre-existing psychotic or bipolar disorders are a contraindication/strong caution [Ref 33]

**Pregnancy:**
- Contraindicated: modafinil is associated with congenital heart defects, hypospadias, and orofacial clefts in post-marketing data [Ref 28, Ref 33]
- Use alternative contraception: modafinil reduces efficacy of oral contraceptives via CYP3A4 induction [Ref 2, Ref 33]; additional or alternative contraception required during treatment and for one month after discontinuation

**Pediatric:**
- Not FDA-approved for any indication in children
- Higher rate of serious dermatological reactions; FDA rejected ADHD approval [Ref 37]

### Common Adverse Effects (therapeutic doses)

| Effect | Incidence |
|--------|-----------|
| Headache | Most common (up to 34%) |
| Nausea | ~11% |
| Decreased appetite | ≤10% |
| Insomnia | ~5% |
| Anxiety | ~5–10% |
| Dizziness | ~5% |
| Hypertension | ~3–4% |

---

## Harm Reduction

### Published Risk Reduction Strategies

1. **Cardiovascular screening:** Contraindicated in patients with pre-existing cardiovascular disease, left-ventricular hypertrophy, uncontrolled hypertension, unstable angina, or recent MI [Ref 28, Ref 33].

2. **Dermatological monitoring:** Discontinue at first sign of any rash, even if benign-appearing — it is not possible to reliably predict which rashes will become serious [Ref 33]. Typically occurs within 1–5 weeks of initiation.

3. **Contraceptive efficacy:** Women using hormonal contraceptives must use backup contraception during modafinil treatment and for 1 month post-discontinuation due to CYP3A4 induction reducing contraceptive steroid levels [Ref 2, Ref 33].

4. **Hepatic/renal impairment:** Reduce dose to 100 mg/day (maximum) in severe hepatic impairment; use with caution in renal insufficiency [Ref 28].

5. **Psychiatric history:** Avoid or use with extreme caution in patients with history of psychosis, mania, hallucinations, or suicidal ideation [Ref 28].

6. **Drug interactions:** Patients on warfarin, cyclosporine, phenytoin, or hormonal contraceptives require monitoring and/or dose adjustment [Ref 2, Ref 28].

7. **Pregnancy avoidance:** Contraindicated in pregnancy due to congenital malformation risk [Ref 28, Ref 33].

8. **Sleep hygiene:** Efficacy does not substitute for adequate sleep; long-term use without addressing underlying sleep disorder is not recommended [Ref 12].

### Emergency Response

Overdose management is supportive:
- Monitor cardiac rhythm, blood pressure, and mental status
- Benzodiazepines for agitation or psychosis as needed
- No specific antidote exists
- Most cases resolve with supportive care; ~80% do not require medical intervention [Ref 28]

---

## Tolerance & Dependence

### Tolerance Development

- **Clinical evidence:** Long-term use of modafinil in narcolepsy patients can lead to tolerance, manifesting as loss of efficacy requiring continuous dose escalation [Ref 45] (Winter et al. 2023 [Ref 45])
- **Mechanism:** Likely involves neuroplastic changes in dopaminergic D2 receptor isoform expression in the mesocorticolimbic system [Ref 46]
- **Tolerance management:** Drug holidays supported by pitolisant bridging have been described as an effective strategy [Ref 45]

### Cross-Tolerance

The brief lists cross-tolerance with "benzhydryl" and "nootropics/nootropic" classes. This is pharmacologically plausible given shared DAT inhibition mechanism with benzhydryl compounds, but no specific published primary studies confirming cross-tolerance with named compounds were found in this research.

### Dependence Liability

- **Physical dependence:** Consistent with published literature — no withdrawal syndrome observed in 14-day cessation study [Ref 28]. Physical dependence has not been formally demonstrated in controlled studies.
- **Psychological dependence:** Published case reports of modafinil dependence are very rare compared to classical stimulants [Ref 1, Ref 4]. The Minzenberg & Carter review [Ref 4] characterizes modafinil as having "a low liability to abuse."
- **Abuse potential:** Confirmed as a DAT blocker that increases nucleus accumbens dopamine (Volkow 2009 [Ref 5]) — hence the DEA Schedule IV placement and the warning about abuse potential in vulnerable populations. However, preclinical and clinical studies consistently show lower reinforcing effects than cocaine or amphetamine [Ref 10].
- **DEA assessment:** Placed in Schedule IV (low but non-trivial abuse potential) in 1999 [Ref 25].

**⚠ FLAG — Brief states "Physical: none; Psychological: none; Formation: not addictive with a low potential for abuse":** This is broadly consistent with the literature for typical clinical use, but slightly understates the risk. Volkow 2009 [Ref 5] explicitly warns about abuse potential in vulnerable populations; Winter 2023 [Ref 45] documents tolerance requiring dose escalation. The generation agent should nuance this to: very low but not zero dependence risk, particularly in vulnerable populations.

---

## Interactions

### Tramadol (Brief rating: "lethal")

**Mechanism:** Modafinil is a CYP3A4 inducer [Ref 2]. Tramadol is metabolized via CYP3A4; modafinil induction accelerates tramadol clearance, potentially reducing analgesic efficacy and causing withdrawal. More critically, **discontinuation of modafinil** in a patient on tramadol can increase tramadol exposure (enzyme induction ceases), raising risk of tramadol toxicity including seizures and respiratory depression. Additionally, both modafinil and tramadol affect monoaminergic systems; tramadol inhibits serotonin and norepinephrine reuptake, and modafinil elevates NE — combined noradrenergic load may increase risk of seizures and cardiovascular events [Ref 2, Ref 28].

**⚠ FLAG — "Lethal" rating for modafinil-tramadol interaction:** No published case report of a fatality specifically attributed to the modafinil-tramadol combination was identified in this literature search. The interaction is categorized as "serious" on drug interaction databases (seizure risk, cardiac rhythm risk, serotonin syndrome risk), but the "lethal" designation in the brief is not directly supported by a primary published source found in this research. This requires editorial review and citation sourcing.

### MDMA (Brief rating: "dangerous")

**Mechanism:** Both modafinil and MDMA increase sympathomimetic drive. Modafinil at 400 mg increases HR (+9.2 bpm), BP (+7.3 mmHg systolic), and catecholamines (+33–81%) [Ref 17]. MDMA independently increases HR and BP through massive monoamine release. Combined use creates additive cardiovascular strain. MDMA's massive serotonin release combined with modafinil's indirect serotonergic effects may also increase risk of serotonergic toxicity [Ref 19]. Dolder et al. 2018 [Ref 19] directly compared MDMA, methylphenidate, and modafinil effects within subjects but did not study combined use.

**⚠ FLAG — "Dangerous" rating for modafinil-MDMA interaction:** No published controlled study or case series specifically studying the modafinil+MDMA combination was identified. The "dangerous" rating is pharmacologically plausible based on additive cardiovascular and monoaminergic effects, but is not confirmed by a specific published human study. This should be labeled as mechanism-inferred rather than study-confirmed.

### Alcohol (Brief rating: "unknown")

No published interaction data was found via the searches conducted. This is consistent with the brief's "unknown" classification.

### Key CYP-Mediated Interactions [Ref 2, Ref 28, Ref 33]

| Drug | Interaction | Mechanism | Severity |
|------|-------------|-----------|----------|
| Oral contraceptives | Reduced efficacy | CYP3A4 induction → lower ethinylestradiol | Major — backup contraception required |
| Triazolam | Reduced levels | CYP3A4 induction | Significant |
| Warfarin | Elevated INR risk | CYP2C9 suppression → warfarin accumulation | Monitor closely |
| Cyclosporine | Reduced levels | CYP3A4 induction | Significant |
| Clozapine | Reduced levels | CYP3A4 induction | Significant |
| Phenytoin | Accumulation risk | CYP2C19 inhibition → phenytoin elevated | Monitor |
| Ketoconazole/ritonavir | Modafinil levels increased | CYP3A4 inhibition → reduced modafinil clearance | Monitor |
| Rifampin | Modafinil levels reduced | CYP3A4 induction | Clinical relevance unclear |
| MAOIs | Potential interaction | Catecholaminergic | Use with caution; no specific studies found |

---

## Legal Status

### United States
- **Scheduling:** DEA Schedule IV under the Controlled Substances Act [Ref 25]
- **Effective date:** January 27, 1999 [Ref 25]
- **FDA approval:** Narcolepsy (1998); shift work sleep disorder and OSA adjunct (2003) [Ref 6]
- **Implications:** Prescription required; refills limited; distribution regulated

### United Kingdom
- **Status:** Prescription-Only Medicine (POM) under the Medicines Act 1968 [web-retrieved]
- **Controlled drug status:** NOT listed under the Misuse of Drugs Act 1971; not a controlled drug in the UK
- **Practical implication:** Legal to possess with a valid prescription; supply without prescription is illegal

### Australia
- **Scheduling:** Schedule 4 (prescription-only medicine) under the Therapeutic Goods Act [web-retrieved]
- **Import:** Illegal to import without a valid Australian prescription

### Canada
- **Status:** Schedule I under the Food and Drugs Act (prescription required) [web-retrieved; not confirmed via primary API]

### European Union
- Prescription required; regulatory status varies by member state; marketed as Modiodal in France and other countries

### International
- Modafinil is NOT currently listed on the International Narcotics Control Board (INCB) list of psychotropic substances under the Convention on Psychotropic Substances (1971) [web-retrieved]. Some secondary sources incorrectly describe it as internationally scheduled — this appears to be erroneous based on INCB documentation reviewed.

---

## Clinical Trials

### FDA-Approved Indications (Completed Key Trials)

| Trial | Phase | Condition | Sponsor | Status |
|-------|-------|-----------|---------|--------|
| NCT00107848 | Phase 3 | Narcolepsy, OSA (pediatric) | Cephalon | COMPLETED |
| NCT00214968 | Phase 3 | Narcolepsy (pediatric) | Cephalon | COMPLETED |
| NCT00214981 | Phase 3 | ADHD (pediatric) | Cephalon | COMPLETED |
| NCT00066170 | Phase 3 | Narcolepsy (sodium oxybate vs modafinil) | Jazz Pharmaceuticals | COMPLETED |

### Off-Label and Investigational (Selected)

| Trial | Phase | Condition | Sponsor | Status |
|-------|-------|-----------|---------|--------|
| NCT00546403 | N/A | Schizophrenia (EDS, negative symptoms) | Veterans Medical Research Foundation | COMPLETED |
| NCT00297284 | N/A | Systemic lupus erythematosus (cognitive) | Hospital for Special Surgery | TERMINATED |
| NCT00626210 | Phase 4 | Insomnia / Alzheimer's (elderly) | VA Palo Alto | TERMINATED |

### Evidence Base Summary

- **Narcolepsy:** Strong evidence across multiple RCTs and network meta-analyses [Ref 27, Ref 22, Ref 47]. Modafinil consistently reduces EDS and improves wakefulness measures.
- **Idiopathic hypersomnia:** Two placebo-controlled trials show improvement in EDS [Ref 34].
- **Shift work sleep disorder / OSA:** FDA-approved based on RCT evidence [Ref 6, Ref 11].
- **Cognitive enhancement in healthy subjects:** Systematic review [Ref 7] confirms executive function enhancement; ~50% of trials show attention/memory improvement; no safety signals at therapeutic doses.
- **Bipolar depression (adjunctive):** Meta-analysis [Ref 20] shows benefit; not FDA-approved.
- **ADHD (pediatric):** RCT [Ref 37] showed efficacy; FDA approval rejected due to SJS dermatological risk.
- **Cocaine dependence:** Mixed results across trials; PET data shows DAT occupancy [Ref 8, Ref 40]; does not reliably reduce cocaine use [Ref 40].
- **MS, PD, TBI fatigue:** Variable results in systematic review [Ref 39]; insufficient evidence for routine recommendation.
- **Military/operational use:** Officially regulated for off-label use in French and other military aviation; effective for short-term fatigue countermeasures [Ref 13, Ref 43].

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Review

1. **⚠ Tramadol interaction severity ("lethal"):** No primary case report of a modafinil-tramadol fatality was identified. Interaction is serious (seizure risk, cardiac rhythm risk, serotonin syndrome potential via noradrenergic/serotonergic mechanisms and CYP3A4 kinetics), but the "lethal" designation is not directly supported by published primary literature found in this research. Recommend sourcing or downgrading to "dangerous."

2. **⚠ MDMA interaction severity ("dangerous"):** No specific study of combined modafinil+MDMA use found. Risk is pharmacologically plausible (additive cardiovascular strain, catecholamine loading) but mechanism-inferred, not study-confirmed. Label as such.

3. **⚠ Tolerance "Half-life: 5 days":** No published study confirming a 5-day tolerance half-life for modafinil was found. This may be an editorial estimate. The elimination half-life is 12–15 hours, not 5 days. Requires citation or removal.

4. **⚠ Toxicity ratings "Acute: high; Chronic: high":** This framing is ambiguous. The literature describes modafinil as having very favorable acute and chronic toxicity at therapeutic doses. The "high" designation appears to mean the LD50 is very high (difficult to reach) — i.e., the drug is hard to kill with, not that it is highly toxic. Recommend clarifying this field semantics.

5. **⚠ Pharmacological class — "Norepinephrine reuptake inhibitor":** Direct NET inhibition is not confirmed by primary binding studies. NE elevation is indirect. Recommend revising to reflect indirect NE effects rather than direct NET inhibition.

### Data Gaps

- **SMILES string:** Not returned by PubChem API in this run; available at CID 4236 on PubChem website
- **LD50 in humans:** Not established; no published case studies describing lethal dose reached
- **CAS number:** 68693-11-8 (web-retrieved, not API-confirmed)
- **Specific Ki values at NET and SERT:** Not found in primary literature retrieved
- **Tramadol-modafinil interaction:** No primary case report identified
- **MDMA-modafinil interaction:** No clinical study identified
- **Alcohol-modafinil interaction:** No published data found
- **Cross-tolerance specifics (benzhydryl):** No primary studies confirming cross-tolerance with specific named agents found
- **Perceptual effects (olfactory hallucination, music enhancement, light sensitivity):** Not documented in controlled primary studies; likely idiosyncratic or user-report-based only
- **Physical properties (melting point, solubility):** Web-retrieved estimates; not confirmed via primary chemistry publication in this research

### Notable Discrepancies

- **Half-life**: Seed brief's "5 days" under tolerance data vs confirmed 12–15 hours elimination half-life [Ref 2]
- **PubChem CID/SMILES**: Missing from brief; now confirmed (CID 4236)
- **Pharmacological class**: "Norepinephrine reuptake inhibitor" overstated relative to published mechanism data